COVID-19 Vaccination Associated With Reduced Postoperative SARS-CoV-2 Infection and Morbidity

Nikhil K. Prasad, MB, ChB,† † Rachel Lake, MSPH,† † Brian R. Englum, MD, MHS,‡ Douglas J. Turner, MD,‡  † Tariq Siddiqui, MS;† Minerva Mayorga-Carlin, MPH; † John D. Sorkin, MD, PhD,‡ †§ and Brajesh K. Lal, MD* † Blal@som.umaryland.edu.

From the †Department of Surgery, University of Maryland School of Medicine, Baltimore, MD; ‡Surgery Service, Veterans Affairs Medical Centre, Baltimore, MD; †Geriatrics Research, Education, and Clinical Center, Veterans Affairs Medical Centre, Baltimore, MD; and §Department of Medicine, University of Maryland School of Medicine, Baltimore, MD.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s Web site (www.annalsofsurgery.com).

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Objective: The purpose of this study was to determine the effect of COVID-19 vaccination on postoperative mortality, pulmonary and thrombotic complications, readmissions and hospital lengths of stay among patients undergoing surgery in the United States.

Background: While vaccination prevents COVID-19, little is known about its impact on postoperative complications.

Methods: This is a nationwide observational cohort study of all 1,255 Veterans Affairs facilities nationwide. We compared patients undergoing surgery at least 2 weeks after their second dose of the Pfizer BioNTech or Moderna vaccines, to contemporary propensity score matched controls. Primary endpoints were 30-day mortality and postoperative COVID-19 infection. Secondary endpoints were pulmonary or thrombotic complications, readmissions, and hospital lengths of stay.

Results: 30,681 patients met inclusion criteria. After matching, there were 3,104 in the vaccination group (1,903 received the Pfizer BioNTech, and 1,201 received the Moderna vaccine) and 7,438 controls. Full COVID-19 vaccination was associated with lower rates of postoperative 30-day COVID-19 infection (Incidence Rate Ratio and 95% confidence intervals, 0.09 [0.01,0.44]), pulmonary complications (0.54 [0.39, 0.72]), thrombotic complications (0.68 [0.46, 0.99]) and decreased hospital lengths of stay (0.78 [0.69, 0.89]). Complications were also low in vaccinated patients who tested COVID-19 positive before surgery but events were too few to detect a significant difference compared to controls.

Conclusion: COVID-19 vaccination is associated with lower rates of postoperative morbidity. The benefit is most pronounced among individuals who have never had a COVID-19 infection before surgery.

Keywords: COVID-19, postoperative complications, vaccines

DOI: 10.1097/SLA.0000000000005176

ISSN: 0003-4932/21/27501-0031
Inclusion and Exclusion Criteria

Our exposure was the receipt of two doses of either the Pfizer BioNTech or Moderna vaccine at least 14 days before undergoing a surgical procedure. Centers for Disease Control and Prevention guidelines state that maximum protection against COVID-19 infection occurs 2 weeks post-vaccination.\(^2\) Study enrollment began January 25, 2021, the date that the first patient fulfilled criteria for maximum vaccine protection and continued until March 25, 2021. Patients who did not receive the vaccine during the study period were enrolled into the control groups.

Data Collection

Information was obtained from the VA Corporate Data Warehouse which stores all data entered into the VA’s electronic medical record.\(^1\) The VA updates and continuously checks the data for accuracy in near real time. Data describing patient age, sex, race (White, Black, and other), ethnicity (Hispanic or Latino), body mass index, smoking status (current, former, or never), and the American Society of Anesthesiologists (ASA) physical status classification (I through VI) were obtained.\(^5\) Medical comorbidities were determined by reviewing International Classification of Disease system-10 (ICD-10) codes. The pre-surgical burden of comorbidity was obtained from the Charlson Comorbidity Index (CCI), a composite score of 17 comorbidities existing during the two years before the date of surgery.\(^6\) The five-digit Current Procedural Terminology (CPT) code describing the procedure in its entirety, case urgency (elective, urgent, or emergency), and type of anesthesia used (general or other, a composite of sedation, spinal, epidural and local) for each procedure were obtained. The organ system undergoing surgery was recorded based on the first two digits of the CPT code. Data on the presence of a positive SARS-CoV-2 PCR test in the medical record at any time point was used to determine time from first positive test to date of surgery.

Outcome Measures

Patients were followed for 30 days after the index procedure. Our co-primary outcome measures were all-cause mortality and a new positive COVID-19 RNA PCR or antigen test after surgery. Secondary outcome measures included composite pulmonary complications (pneumonia, mechanical ventilation, acute respiratory distress syndrome, or acute respiratory failure), composite thrombotic complications (deep vein thrombosis, pulmonary embolism, myocardial infarction, ischemic stroke, and arterial thrombosis), hospital readmissions, and in-hospital lengths of stay. The secondary outcomes were identified by using ICD10 codes and admission, discharge, outpatient, and transfer records. ICD-10 and CPT codes were used to identify mechanical ventilation.

Statistical Analysis

We compared the demographic, clinical and procedural characteristics of the vaccination and control groups using frequencies and percentages, means and standard deviations, or medians and interquartile ranges (IQR). Comparisons of categorical data were performed using Pearson \(\chi^2\) test or Fisher Exact test when cell sizes were 5 or less. Student \(t\)-test was used to compare normally distributed continuous data between study groups, and the Mann-Whitney- \(U\) test was used for non-normally distributed continuous data.

The primary analysis compared all completely vaccinated patients undergoing surgery to all unvaccinated patients undergoing surgery; two separate secondary analyses compared vaccinated to unvaccinated patients who tested positive for COVID-19 before surgery, and who had no history of having had COVID-19 before surgery respectively. For all three analyses, we used a combination of exact and propensity score matching (propensity to have received vaccination) to create control groups that closely matched their respective vaccination groups. A separate match was performed for each of the three analyses. Patients in the control group were matched 3:1 to the vaccination group with an exact match on all five digits of the CPT code (fully defining the procedure). A greedy nearest neighbor match was performed on race, ethnicity, CCI, ASA class, smoking status, case urgency, and anesthesia type using a caliper of 0.25. The matching minimizes the standardized mean differences in propensity scores between the two groups.\(^7\) The unadjusted primary and secondary outcome events and rates were computed for each group. Multivariable Poisson regression models adjusting for factors that were not balanced after propensity score matching in each analysis were used to determine the effect of vaccination on rates of mortality, pulmonary and thrombotic complications, readmissions and length of stay. An incidence rate ratio (IRR) with 95% confidence intervals (CI) was computed that compared each outcome measure between the groups. A two-sided \(\alpha\) of \(\leq 0.05\) was considered statistically significant.

We performed two subgroup analyses. First we compared outcomes among those who tested COVID-19 positive after surgery with those who did not, in vaccinated and unvaccinated patients. Second we compared outcomes for cardiovascular, respiratory, and gastrointestinal procedures, as defined by the first two digits of CPT code in vaccinated and unvaccinated patients. In the second subgroup analysis we followed the same rubric for propensity score matching as the primary analysis and calculated the relative complication rate of vaccinated to unvaccinated controls after adjusting for age and CCI. All statistical analyses were performed using R version 4.0.3 (R Foundation for Statistical Computing, Vienna, Austria) with the following packages- gtable, dplyr, and matchit.

RESULTS

A total of 30,681 patients underwent a surgical procedure during the study period of January 25 to March 25, 2021 (Fig. 1). For the primary analysis, after excluding those with missing data \((n = 1,100)\), 3,924 patients met criteria for inclusion in the vaccination group and 25,657 met criteria for the control group. After propensity score matching, there were 3,104 patients in the vaccination group (1903 received the Pfizer BioNTech vaccine and 1,201 received the Moderna Vaccine) and 7,438 patients in the control group. Patients were well matched on sex, race and ethnicity, body mass index, smoking status, case urgency, ASA class and organ system undergoing surgery (Table 1). Vaccinated patients were older \((P < 0.001)\) and had a higher CCI \((P < 0.001)\) compared to controls.

In unadjusted analyses, the vaccination group had a lower rate of 30-day postoperative COVID-19 infection \((0.0%\) vs. \(0.3%)\) but a similar all-cause mortality rate \((0.4%\) vs. \(0.6%)\) compared to non-vaccinated controls (Table 2). The vaccination group had fewer pulmonary complications \((1.7%\) vs. \(3.0%)\), thrombotic complications \((1.1%\) vs \(1.5%)\) and shorter hospital lengths of stay \([median (inter-quartile range), 2 (1, 5) vs. 2(1,6)]\), but similar rates of readmissions compared to controls. Multivariable models adjusted for age and CCI (Table 2) showed that the vaccination group had a lower incidence rate ratio \((95% confidence intervals) of 30-day postoperative COVID-19 infection \([0.09, (0.01,0.44)]\), pulmonary complications \([0.54, (0.39–0.72)]\), thrombotic complications \([0.68, (0.46–0.99)]\) and shorter hospital lengths of stay \([0.78 (0.69,0.89)]\) compared to the control group. The second analysis compared vaccinated and control patients who never tested COVID-19 positive before surgery. The exact CPT matching followed by propensity score matching resulted in two groups (vaccine group, \(n = 2876\) and control group \(n = 6971\)) that were not different with respect to demographics, clinical or procedural characteristics except for age \([median (IQR) 71.7 (67.76) vs 71 (65,75), P < 0.001]\) and CCI \([2 (1.4) vs 2 (1.4), P < 0.001]\) being
higher, and general anesthesia being used more frequently (42.6% vs 40.3%, \( p = 0.04 \)) in the vaccination group compared to controls (Supplementary material, http://links.lww.com/SLA/D404). In the unadjusted analysis, vaccination was associated with fewer 30-day postoperative COVID-19 infections (0.0 vs 0.4%, \( p = 0.04 \)) and hospital lengths of stay (median 2 [1.5] vs 2 [1.6]) (Supplementary material, http://links.lww.com/SLA/D404). In a multivariable model that adjusted for age, CCI, and anesthesia type, vaccination was associated with lower rates of postoperative COVID-19 (incidence rate ratio 0.09, 95% CI 0.00–0.40), pulmonary complications (0.57, 95% CI 0.42–0.78) and hospital lengths of stay (0.8 (0.71, 0.91)) compared to controls (Supplementary material, http://links.lww.com/SLA/D404). (Vac-}

cine group, \( n = 2876 \) and control group \( n = 6971 \) \( \text{(Supple-}

cmentary material, http://links.lww.com/SLA/D404)\). The vaccination group had no deaths (n = 1 in the control group), 2 patients had pulmonary complications (n = 10 in the control group), 1 had a thrombotic complication (n = 2 in the control group) and 2 patients were readmitted (n = 11 in the control group). The median [IQR] hospital length of stay was 2 [1, 4] in the vaccinated group vs 2 [1, 4.25] in controls (Supplementary material, http://links.lww.com/SLA/D404). The event rates were too low in either group to perform reliable comparisons.

In the first subgroup analysis unvaccinated patients who developed postoperative COVID-19, when compared to vaccinated patients who did not, had higher mortality (2.5% vs. 0.6%), composite pulmonary complications (19.8% vs. 2.2%), composite thrombotic complications (6.2% vs. 1.3%), readmission rates (27.2% vs. 3.4%); and longer lengths of stay (7 vs. 2 days) (Supplementary materials, http://links.lww.com/SLA/D404). In the second subgroup analysis, vaccinated compared to unvaccinated patients undergoing cardiovascular, respiratory, and gastrointestinal procedures had lower pulmonary complication rates (0.37, 95% CI 0.24–0.55) and lower thrombotic complication rates (0.38, 0.32–0.99) (Supplementary data, http://links.lww.com/SLA/D404).

**DISCUSSION**

We present the first report demonstrating the perioperative benefits of complete vaccination against COVID-19. In a comparison of two groups undergoing surgery that were matched on demographic features, comorbidities, and procedural characteristics, patients who received COVID-19 vaccination before surgery had fewer postoperative COVID-19 infections (0.0% vs. 0.3%, adjusted IRR (95% CI) 0.09 (0.01, 0.44)), pulmonary complications (1.7% vs. 3.0%, 0.54 (0.39,0.72)), thrombotic complications (1.1% vs. 1.5%, 0.68 (0.46, 0.99)) and shorter hospital lengths of stay [0.78 (0.69,0.89)]. Mortality [0.4% vs. 0.6%, 0.63 (0.32, 1.13)] and readmissions [3.1% vs. 3.7%, 0.8 (0.63,1.00)] did not differ between the two groups. Patients who had never had a COVID-19 infection before surgery benefited from vaccination. While patients who tested COVID-19 positive before surgery also showed nominally fewer postoperative complications, the event rates were too low to reliably detect differences. Subgroup analyses confirmed our previous findings of elevated complications associated with postoperative COVID-19 infection\(^7\) and reduction in pulmonary and thrombotic complications associated with vaccination was more pronounced when we restricted the cohort to patients undergoing cardiovascular, pulmonary and gastrointestinal procedures. These results are important for two reasons: 1) they demonstrate the efficacy of COVID-19 vaccine in reducing postoperative SARS-CoV-2 infections in a cohort of older adults with high
TABLE 1. Comparison of Characteristics of Vaccinated Patients Undergoing Surgery Versus Propensity Score Matched Patients Undergoing Surgery Without Prior Vaccination

|                | Control N = 7438 (%) | Vaccine N = 3104 (%) | P-value |
|----------------|----------------------|----------------------|---------|
| Age, median (IQR), yr | 71.00 [66.00, 75.00] | 72.00 [67.00, 76.00] | <0.001  |
| Sex (Male)      | 7007 (94.2)          | 2937 (94.6)          | 0.428   |
| Race/ethnicity  |                      |                      | 0.577   |
| White           | 5474 (73.6)          | 2277 (73.4)          |         |
| Black           | 1470 (19.8)          | 634 (20.4)           |         |
| other           | 494 (6.6)            | 193 (6.2)            |         |
| Hispanic or Latino | 426 (5.7)          | 172 (5.5)            | 0.741   |
| Body Mass Index | 29.84 (6.01)         | 29.63 (5.93)         | 0.103   |
| Smoking status  |                      |                      | 0.686   |
| Current Smoker  | 1101 (14.8)          | 441 (14.2)           |         |
| Former Smoker   | 3983 (53.5)          | 1663 (53.6)          |         |
| Never Smoker    | 2354 (31.6)          | 1000 (32.2)          |         |
| Charlson comorbidity index (median [IQR]) | 2.00 [1.00, 4.00] | 2.00 [1.00, 4.00] | <0.001  |
| General anesthesia | 3004 (40.4)        | 1312 (42.3)          | 0.077   |
| Case urgency    |                      |                      | 0.331   |
| Elective        | 6206 (83.4)          | 2555 (82.3)          |         |
| Urgent          | 1134 (15.2)          | 509 (16.4)           |         |
| Emergency       | 98 (1.3)             | 40 (1.3)             |         |
| ASA Class       |                      |                      | 0.183   |
| I               | 17 (0.2)             | 6 (0.2)              |         |
| II              | 855 (11.5)           | 345 (11.1)           |         |
| III             | 5732 (77.1)          | 2359 (76.0)          |         |
| IV              | 834 (11.2)           | 394 (12.7)           |         |
| Organ System    |                      |                      | 0.084   |
| Cardiovascular  | 539 (7.2)            | 275 (8.9)            |         |
| Gastrointestinal | 1026 (13.8)         | 432 (13.9)           |         |
| Integumentary   | 353 (4.7)            | 156 (5.0)            |         |
| Musculoskeletal | 1176 (15.8)          | 481 (15.5)           |         |
| Neurological    | 375 (5.0)            | 166 (5.3)            |         |
| Ophthalmological | 2265 (30.5)        | 871 (28.1)           |         |
| Respiratory     | 253 (3.4)            | 117 (3.8)            |         |
| Urology         | 1318 (17.7)          | 544 (17.5)           |         |

ASA indicates American Society of Anesthesiologists; CPT, current procedural terminology; FNA, fine-needle aspiration; IQR, interquartile range.

*Other includes Asian, American Indian or Alaskan Native, Native Hawaiian or Other Pacific Islander.

†Definition of the organ system is based on the first two digits of the CPT code. The following procedure types were excluded due to low proportions: miscellaneous, mediastinum/diaphragm, operating microscope, lymphatic, gynecological, maternity care, FNA procedures, endocrine, and auditory.

Comorbidity burden, and 2) they demonstrate a reduction in COVID-19-related postoperative complications.

Ongoing clinical trials have demonstrated an efficacy of 95% for the Pfizer BioNTech vaccine and 94.1% for the Moderna vaccine for preventing COVID-19 infection. Recent real-world data confirm the efficacy of the Pfizer and Moderna COVID-19 vaccines in preventing infection and have also shown effectiveness in reducing hospitalizations and mortality. However, surgical procedures

TABLE 2. Primary and Secondary Outcomes in Vaccinated Patients Undergoing Surgery Versus Propensity Score Matched Patients Undergoing Surgery Without Prior Vaccination

|                     | Control N = 7438 (%) | Vaccine N = 3104 (%) | IRR(95% CI) | P-value |
|---------------------|----------------------|----------------------|-------------|---------|
| Mortality           | 45 (0.6)             | 13 (0.4)             | 0.63 (0.32,1.13) | 0.14    |
| COVID-19 positive after surgery | 25 (0.3)         | 1 (0.0)              | 0.09 (0.01,0.44) | 0.02    |
| Composite pulmonary complications | 222 (3.0)    | 53 (1.7)             | 0.54 (0.39,0.72) | <0.001  |
| Composite thrombotic complications | 114 (1.5)   | 35 (1.1)             | 0.68 (0.46,0.99) | 0.05    |
| Readmissions        | 277 (3.7)            | 97 (3.1)             | 0.8 (0.63,1.00)  | 0.06    |
| Hospital length of stay (median [IQR]) | 2.00 [1.00, 6.00] | 2.00 [1.00, 5.00] | 0.78 (0.69,0.89) | <0.001  |

CCI indicates Charlson Comorbidity Index; CI, confidence interval; IQR, interquartile range; IRR, incidence rate ratio.

*Reference event numbers and unadjusted rates.

†Incidence rate ratio with Control group as Reference (1.00) in a Poisson regression model adjusting for age and CCI.

‡P-value for incidence rate ratio adjusting for age and CCI.
performed on COVID-positive patients are associated with increased 30-day mortality, postoperative pneumonia and need for unexpected mechanical ventilation. The consequent broad moratorium on elective surgery during the height of the pandemic surge led to widespread disruption in hospital services across the world. Surgery is gradually being reinstated with recommendations for delaying the procedure in those that test COVID-19 positive on preoperative screening. These delays are resulting in large backlogs in elective surgery with potential delays in treatment for time-sensitive diseases such as cancers. Our results demonstrate for the first time, that vaccination for COVID-19 accomplished at least 2 weeks before surgery is associated with lower rates of postoperative COVID-19 infection, pulmonary and thrombotic complications, and shorter hospital length of stay. The fact that the benefit included COVID-19 negative patients has important implications for current guidelines for surgical services. In patients that test negative on preoperative screening and are planned for non-time-sensitive elective surgery, full vaccination will likely yield the best postoperative outcomes. Time-sensitive urgent or emergency surgeries are still best served by proceeding as planned after a negative screening test for COVID-19.

Updated guidelines from the American Society of Anesthesiologists recommend that elective surgery be delayed for 4 weeks in most patients with mild COVID-19 disease and up to 10 weeks for immunocompromised patients. This is based on reports that the risk of perioperative complications due to COVID-19 can persist for at least 4 weeks and up to 7 weeks. The implicit assumption is that delaying surgery would prevent COVID-related postoperative complications. Our results did not show a significant reduction in the primary or secondary endpoints among patients with prior COVID-19 infection who underwent surgery thereafter. This is in keeping with reports that COVID infection is typically associated with generation of protective antibodies that can last up to 8 months. At present there is no reliable data on how long immunity lasts after infection, and further work is needed to evaluate the long-term sequelae of COVID-19 infection. One interpretation of our findings may be that once infected and recovered from COVID-19, patients may undergo surgery without vaccination. However, our data also showed nominally fewer pulmonary complications (n = 2 vs. n = 101) and readmissions (n = 2 vs. n = 11) among vaccinated patients with prior COVID-19 infection. Our cohort for this analysis included patients who had tested positive for COVID-19 before surgery at any time since the commencement of the pandemic. More studies are needed to determine if this is the beginning of a pattern highlighting a potential for diminished immune protection from remote COVID-19 infection over time. Therefore, vaccination must not be avoided in this group of patients.

Infection with the SARS-CoV-2 virus is associated with pulmonary and extrapulmonary manifestations due to viral entry via the Angiotensin-converting enzyme 2 receptor, a target that is distributed widely throughout the body. Coronaviridae are capable of mutation, producing variants that may elude existing molecular diagnostic tests, depending on the target genes or proteins being evaluated. This is of sufficient concern that the United States Food and Drug Administration released an open letter on January 8, 2021 warning about the potential for false negative tests in the setting of SARS-CoV-2 viral mutation. We noted a reduction in the rate of pulmonary and thrombotic complications among vaccinated individuals that is not sufficiently accounted for by the reduction in rates of postoperative COVID-19 infections alone. These data have two potential explanations. Vaccination was associated with a reduction in pulmonary and thrombotic complications attributable to SARS-CoV-2 infections that were potentially missed by available molecular testing (false negatives). However, a potential pleiotropic effect of the mRNA vaccines cannot be excluded. More experience with the vaccines will clarify these mechanisms.

We acknowledge the limitations of using administrative data combined with information from an electronic medical record. In addition, our cohort consisted of older male Veterans with comorbidity rates higher than in the general population. However, their demographic features and comorbidities represent the population at highest risk for the sequelae of COVID-19 and are therefore an ideal cohort for the analysis. It should also be noted that a large proportion of the procedures performed were outpatient and low operative risk, which may have affected the results. While the beneficial effect of vaccination appears to be consistent, the magnitude of the protective effect remains to be determined in other populations and specific procedures. It is possible that the differences in treatment effect would be smaller in younger, healthier patients. While the study was well-powered for the first two analyses, the sample size for the third analysis (preoperative COVID-positive patients) was small. The retrospective allocation of patients to intervention or control groups may have introduced bias from selection. We do not anticipate the possibility of a randomized study in the near future to test the hypotheses, therefore propensity matching along with exact matching on surgical procedure remains a reliable means of assessment. We acknowledge that the balance on matching was not perfect but were still able to adjust for the imbalance covariates (age and CCI) in a multivariable regression. Finally, the specific cause of death was not available in our dataset, limiting conclusions that can be drawn about differences in morality rates. Overall, this study represents the first nationwide assessment of the contribution of the COVID-19 vaccines in reducing postoperative complications.

CONCLUSIONS

Complete vaccination for COVID-19 using the Pfizer or Moderna vaccines two weeks before undergoing a surgical procedure is associated with lower postoperative morbidity. This protective effect may extend to patients who have never previously tested COVID-19 positive.

REFERENCES

1. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2033–2045.
2. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384:403–416.
3. Ramsamy MN, Minnassian AM, Eweer KJ, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet (London, England). 2021;396:1979–1993.
4. Voysey M, Clemens SAC, Madhu S/A, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet (London, England). 2021;397:99–111.
5. Palacios R, Patito EG, de Oliveira Fisiorei R, et al. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adubred COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21:853.
6. Folegatti PM, Eweer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet (London, England). 2020;396:467–478.
7. Lal BK, Prasad NK, Elguenm BR, et al. Periprocedural complications in patients with SARS-CoV-2 infection compared to those without infection: a nationwide propensity-matched analysis. Am J Surg. 2020;222:431–437.
8. Nepogodiev D, Bhanja A, Glasbeck JC, et al. Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study. Lancet. 2020;396:27–38.
9. Lei S, Jiang F, Su W, et al. Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection. ClinicalMedicine. 2020;21:100335.
10. Doglietto F, Vezzoli M, Gheza F, et al. Factors associated with surgical mortality and complications among patients with and without coronavirus disease 2019 (COVID-19) in Italy. *JAMA Surg*. 2020;155:691–702.

11. Glasbey JC, Nepogodiev D, Omar O, et al. Delaying surgery for patients with a previous SARS-CoV-2 infection. *Br J Surg*. 2020;107:e601–e602.

12. Veterans Affairs Health Administration, U.S. Department of Veterans Affairs. Available at: https://www.va.gov/health/. Published 2020. Accessed September 15, 2020.

13. When You’ve Been Fully Vaccinated | CDC. Available at: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/fully-vaccinated.html. Accessed March 23, 2021.

14. U.S. Department of Veterans Affairs. VA Informatics and Computing Infrastructure (VINCI) homepage. 2018. Available at: https://www.hsrd.research.va.gov/for_researchers/vinci/. Accessed September 28, 2020.

15. Mayhew D, Mendonca V, Murthy BVS. A review of ASA physical status – historical perspectives and modern developments. *Anaesthesia*. 2019;74:373–379.

16. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. *Med Care*. 2005;43:1130–1139.

17. Prasad NK, Lake R, Englund BR, et al. Increased complications in patients who test COVID-19 positive after elective surgery and implications for pre and postoperative screening. *Am J Surg*. 2021;S0002-9610(21)00234-8.

18. FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine | FDA. Available at: https://www.fda.gov/news-events/press-announcements/fda-takes-additional-action-fight-against-covid-19-issuing-emergency-use-authorization-second-covid. Accessed March 23, 2021.

19. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. *N Engl J Med*. 2021;384:1412–1423.

20. New data show vaccines reduce severe COVID-19 in older adults - GOV.UK. Available at: https://www.gov.uk/government/news/new-data-show-vaccines-reduce-severe-covid-19-in-older-adults. Accessed March 23, 2021.

21. Fonseca GA, Normando PG, Loureiro LVM, et al. Reduction in the number of procedures and hospitalizations and increase in cancer mortality during the COVID-19 pandemic in Brazil. *J Glob Oncol*. 2021;7:4–9.

22. ASA and APSF Joint Statement on Elective Surgery and Anesthesia for Patients after COVID-19 Infection. Available at: https://www.asahq.org/about-asa/newsroom/news-releases/2020/12/asa-and-apsf-joint-statement-on-elective-surgery-and-anesthesia-for-patients-after-covid-19-infection. Accessed March 29, 2021.

23. Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study. *Anaesthesia*. 2021;76:748–758.

24. Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for greater than six months after infection. *bioRxiv*. 2020;2020.371.eabf4063.

25. Gupta A, Madhavan MV, Sehgal K, et al. Extrapulmonary manifestations of COVID-19. *Nat Med*. 2020;26:1017–1032.

26. Wang R, Hozumi Y, Yin C, et al. Mutations on COVID-19 diagnostic targets. *Genomics*. 2020;112:5204–5213.

27. Genetic Variants of SARS-CoV-2 May Lead to False Negative Results with Molecular Tests for Detection of SARS-CoV-2 - Letter to Clinical Laboratory Staff and Health Care Providers | FDA. Available at: https://www.fda.gov/medical-devices/letters-health-care-providers/genetic-variants-sars-cov-2-may-lead-false-negative-results-molecular-tests-detection-sars-cov-2. Accessed April 5, 2021.